Property and equipment consist of the following (in thousands):


	As of
	June 30, 2026			December 31, 2025
Lab equipment	$	7,009		$	6,423
Leasehold improvements		28,409			28,265
Computer equipment		1,060			1,075
Furniture and fixtures		1,135			1,122
Software		325			325
Vehicles		96			96
Construction in process		4			27
		38,038			37,333
Less accumulated depreciation		(14,235	)		(12,516	)
Total property and equipment, net	$	23,803		$	24,817

Depreciation expense was $0.9 million and $1.8 million for the three and six months ended June 30, 2026 and 2025, respectively.

Intangible assets, excluding goodwill, consist of the following (in thousands):


	June 30, 2026							December 31, 2025
	Cost		Accumulated Amortization			Net Carrying Value		Cost		Accumulated Amortization			Net Carrying Value
Intangible assets subject to amortization
Patents	$	1,860	$	(879	)	$	981	$	1,953	$	(1,003	)	$	950
Purchased technology		16,900		(15,022	)		1,878		16,900		(14,084	)		2,816
Intangible assets not subject to amortization
Trademarks		120		—			120		117		—			117
Total	$	18,880	$	(15,901	)	$	2,979	$	18,970	$	(15,087	)	$	3,883

Amortization expense related to definite-lived intangible assets was $0.5 million and $1.0 million for the three and six months ended June 30, 2026 and 2025, respectively.

Future estimated amortization expense of intangible assets is (in thousands):


	As of June 30, 2026
Remainder of 2026	$	1,008
2027		1,056
2028		110
2029		110
2030		108
2031 and thereafter		467
Total	$	2,859

Accrued liabilities consist of the following (in thousands):


	As of
	June 30, 2026		December 31, 2025
Compensation related accruals	$	7,383	$	7,834
Accrued clinical trial expenses		799		767
Other expenses		2,229		2,432
Total accrued liabilities	$	10,411	$	11,033